Gore Akshata, Viswanatha Swamy Agadi Hiremath, Bharamu Nyamagoud Sanatkumar
Department of Pharmacy Practice, KLE College of Pharmacy, Vidyanagar, Hubballi, Karnataka.
Monaldi Arch Chest Dis. 2025 Aug 5. doi: 10.4081/monaldi.2025.3340.
Nafithromycin (WCK 4873) is a novel lactone ketolide antibiotic developed to address the critical issue of multidrug-resistant bacteria, especially those causing community-acquired pneumonia (CAP). Given the increasing prevalence of antibiotic resistance, there is a pressing need for new antibiotics with improved efficacy and safety profiles. This review synthesizes data from various in vitro studies and clinical trials to evaluate the pharmacological properties, mechanism of action, and clinical potential of nafithromycin. Key clinical trials assessed the drug's pharmacokinetics, safety, and efficacy in both healthy volunteers and patients with CAP. Nafithromycin exhibits strong in vitro antimicrobial activity against a broad spectrum of pathogens, including macrolide-resistant and telithromycin-insensitive strains. Clinical trials demonstrated that nafithromycin has a favorable pharmacokinetic profile, with high lung tissue concentrations and manageable side effects. Phase I studies confirmed its safety and tolerability in healthy adults, while Phase II trials showed its efficacy in treating CAP, with a 3-day treatment regimen proving comparable to a seven-day regimen of moxifloxacin. Nafithromycin holds significant promise as a therapeutic agent against respiratory infections caused by resistant bacteria. Its unique mechanism of action, high tissue penetration, and broad-spectrum activity position it as a valuable addition to the antimicrobial arsenal. Continued research and clinical trials are essential to further define its role in combating antibiotic resistance and ensuring effective treatment options.
萘夫西林（WCK 4873）是一种新型内酯类酮内酯抗生素，旨在解决多重耐药菌的关键问题，尤其是那些引起社区获得性肺炎（CAP）的细菌。鉴于抗生素耐药性的日益普遍，迫切需要具有更高疗效和安全性的新型抗生素。本综述综合了各种体外研究和临床试验的数据，以评估萘夫西林的药理学特性、作用机制和临床潜力。关键临床试验评估了该药物在健康志愿者和CAP患者中的药代动力学、安全性和疗效。萘夫西林对包括耐大环内酯类和对泰利霉素不敏感菌株在内的广泛病原体具有强大的体外抗菌活性。临床试验表明，萘夫西林具有良好的药代动力学特征，肺组织浓度高且副作用可控。I期研究证实了其在健康成年人中的安全性和耐受性，而II期试验表明其在治疗CAP方面的疗效，3天治疗方案被证明与莫西沙星7天方案相当。萘夫西林作为治疗耐药菌引起的呼吸道感染的治疗药物具有巨大潜力。其独特的作用机制、高组织穿透力和广谱活性使其成为抗菌药物库中的宝贵补充。持续的研究和临床试验对于进一步确定其在对抗抗生素耐药性和确保有效治疗选择方面的作用至关重要。
